271 related articles for article (PubMed ID: 21444285)
1. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
Tofthagen C; McAllister RD; McMillan SC
Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.
Mols F; Beijers T; Lemmens V; van den Hurk CJ; Vreugdenhil G; van de Poll-Franse LV
J Clin Oncol; 2013 Jul; 31(21):2699-707. PubMed ID: 23775951
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
[TBL] [Abstract][Full Text] [Related]
4. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin: a novel platinum analog with activity in colorectal cancer.
Berg D
Oncol Nurs Forum; 2003; 30(6):957-66. PubMed ID: 14603353
[TBL] [Abstract][Full Text] [Related]
7. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents.
Ushio S; Egashira N; Sada H; Kawashiri T; Shirahama M; Masuguchi K; Oishi R
Eur J Cancer; 2012 Jun; 48(9):1407-13. PubMed ID: 21907570
[TBL] [Abstract][Full Text] [Related]
8. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
10. Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system.
Binder A; Stengel M; Maag R; Wasner G; Schoch R; Moosig F; Schommer B; Baron R
Eur J Cancer; 2007 Dec; 43(18):2658-63. PubMed ID: 17855072
[TBL] [Abstract][Full Text] [Related]
11. Patient perceptions associated with chemotherapy-induced peripheral neuropathy.
Tofthagen C
Clin J Oncol Nurs; 2010 Jun; 14(3):E22-8. PubMed ID: 20529785
[TBL] [Abstract][Full Text] [Related]
12. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
Tofthagen C; Donovan KA; Morgan MA; Shibata D; Yeh Y
Support Care Cancer; 2013 Dec; 21(12):3307-13. PubMed ID: 23903798
[TBL] [Abstract][Full Text] [Related]
14. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.
Gent P; Massey K
Int J Palliat Nurs; 2001 Jul; 7(7):354-9. PubMed ID: 11951404
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
[TBL] [Abstract][Full Text] [Related]
16. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
[TBL] [Abstract][Full Text] [Related]
18. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums.
Smith EM; Cohen JA; Pett MA; Beck SL
Cancer Nurs; 2010; 33(3):173-83. PubMed ID: 20357656
[TBL] [Abstract][Full Text] [Related]
19. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
[TBL] [Abstract][Full Text] [Related]
20. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
Tatsushima Y; Egashira N; Narishige Y; Fukui S; Kawashiri T; Yamauchi Y; Oishi R
Biomed Pharmacother; 2013 Feb; 67(1):39-42. PubMed ID: 23206755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]